J Clin Endocrinol Metab (2021) 106(3):91221
The American Gut Project which had over 10k participants found that BMI and Akkermansia inversely correlated across the entire study population: 10% higher Akkermansia reduces risk for obesity approximately 26% on average
Gastrointestinal side effects demonstrated higher incidence compared to GLP-1 monotherapy (nausea 66% vs
10.1016/S2213-8587(18)30104-9 [DOI] [PubMed] [Google Scholar] Verma S, McGuire DK, Bain SC, Bhatt DL, Leiter LA, Mazer CD et al (2020) Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: results of the LEADER and SUSTAIN 6 trials
These agents have been supported by important clinical trials, including Satiety and Clinical Adipose Liraglutide Evidence (SCALE), Semaglutide Treatment Effect in People with Obesity (STEP) program trials, and Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) (44)
